Bottom line
Is FHLC a good fund? The bottom line
FHLC is an index health care sector ETF from Fidelity.
Annual fees run 0.084% — about $8.4 a year on every $10,000 invested, cheaper than 99% of health care sector funds we track.
It returned +2.6% over one year, +7.2% a year over five years, +8.8% a year over ten (as of Nov 30, 2025, per its prospectus).
With $3.3 billion in net assets and 337 holdings, its largest position is Eli Lilly & Co (13.3%) and the top 10 make up 51.9% of the portfolio.
The closest lower-cost alternative we found is XLV (0.08%, 98% top-holdings overlap).
What stands out
- Low cost: cheaper than 99% of health care sector peers
- 5-year return beat 87% of category peers
- Broadly diversified (337 holdings)
What to watch
- Concentrated: top 10 holdings are 51.9% of assets
Updated Nov 19, 2026
What FHLC invests in
Fidelity MSCI Health Care Index ETF seeks to provide investment returns that correspond, before fees and expenses, generally to the performance of the MSCI USA IMI Health Care 25/50 Index.
"Investing at least 80% of assets in securities included in the MSCI USA IMI Health Care 25/50 Index. The MSCI USA IMI Health Care 25/50 Index represents the performance of the health care sector in the U.S. equity market. The index consists of U.S. companies that are classified in the health care sector according to the GICS . The GICS health care sector encompasses two main industry groups. The first group includes companies that manufacture health care equipment and supply or provide health care related services, including distributors of health care products, providers of basic health-care services, and owners and operators of health care facilities and organizations. The second group includes companies primarily involved in the research, development, production and marketing of pharmaceuticals and biotechnology products. Effective December 11, 2025, derivative instruments that…
From the fund's prospectus (filed Nov 24, 2025).
FHLC performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| FHLC | +2.6% | +7.2% | +8.8% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Nov 30, 2025
What FHLC costs
On a $10,000 investment, FHLC's 0.084% expense ratio costs about $8.4 a year. The prospectus estimates $108 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
FHLC top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Eli Lilly & Co | 13.35% |
| 2 | Johnson & Johnson | 8.93% |
| 3 | AbbVie Inc | 6.42% |
| 4 | UnitedHealth Group Inc | 5.44% |
| 5 | Merck & Co Inc | 4.66% |
| 6 | Thermo Fisher Scientific Inc | 3.09% |
| 7 | Amgen Inc | 3.00% |
| 8 | Abbott Laboratories | 2.66% |
| 9 | Gilead Sciences Inc | 2.34% |
| 10 | Pfizer Inc | 2.06% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 51.9% of the fund. See all top 25 holdings and asset mix →
Alternatives to FHLC
| Family | Fund | Expense ratio | Overlap | |
|---|---|---|---|---|
| SPDR (State Street) | XLV State Street(R) Health Care Select… | 0.08% | 98% | Compare |
| Vanguard | VHT Vanguard Health Care Index Fund | 0.09% | 94% | Compare |
| iShares | IYH iShares U.S. Healthcare ETF | 0.37% | 91% | Compare |
| J.P. Morgan | JDOC JPMorgan Healthcare Leaders ETF | 0.65% | 63% | Compare |
| Schwab | SWHFX Schwab Health Care Fund | 0.8% | 76% | Compare |
| T. Rowe Price | PRHSX T. Rowe Price Health Sciences Fund, Inc. | 0.83% | 78% | Compare |